Tarek Sahmoud, MD, PhD
Dr. Sahmoud has more than 25 years of experience in oncology drug development and medical affairs, most recently as Chief Medical Officer of H3 Biomedicines. Tarek also held senior clinical development positions at Celgene, Novartis, and AstraZeneca. During his career, Tarek has either led or supported global drug development programs for several novel oncology drugs in multiple indications, including adjuvant breast cancer (Arimidex), hormone receptor positive breast cancer (Kisqali and Afinitor), resulting in successful global registrations. His experience also includes the development and leading of global and US medical affairs teams, multi-disciplinary teams of physicians and clinical scientists, as well as serving as on the protocol review committee of a number of companies.
Dr. Sahmoud received his medical degree from Cairo University Medical School, Egypt and a Ph.D. in biostatistics from University Bordeaux II, France.